RU2015125349A - МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) - Google Patents

МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) Download PDF

Info

Publication number
RU2015125349A
RU2015125349A RU2015125349A RU2015125349A RU2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A
Authority
RU
Russia
Prior art keywords
amino acid
seq
acid sequence
variable region
nos
Prior art date
Application number
RU2015125349A
Other languages
English (en)
Russian (ru)
Inventor
Сяоянь ЧЖАО
Чжуочжи ВАН
Цзяньмин ГУ
Чжиён КИМ
Максин БОЗОН
Джон Э. Мёрфи
Керк МАКЛИН
Фан ЦЗИНЬ
Тобиас МАРКВУАРДТ
Синьцуань ВАН
Андреас Вильмен
Original Assignee
Байер Хелскеа Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Хелскеа Ллк filed Critical Байер Хелскеа Ллк
Publication of RU2015125349A publication Critical patent/RU2015125349A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015125349A 2012-11-29 2013-11-27 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) RU2015125349A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261731294P 2012-11-29 2012-11-29
US61/731,294 2012-11-29
US201361786472P 2013-03-15 2013-03-15
US61/786,472 2013-03-15
PCT/US2013/072243 WO2014085596A1 (en) 2012-11-29 2013-11-27 MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)

Publications (1)

Publication Number Publication Date
RU2015125349A true RU2015125349A (ru) 2017-01-10

Family

ID=50828462

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015125349A RU2015125349A (ru) 2012-11-29 2013-11-27 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)

Country Status (18)

Country Link
US (1) US20150307625A1 (https=)
EP (1) EP2925351A4 (https=)
JP (1) JP2016501230A (https=)
KR (1) KR20150088869A (https=)
CN (1) CN104812402A (https=)
AR (1) AR093671A1 (https=)
AU (1) AU2013352159A1 (https=)
BR (1) BR112015012414A2 (https=)
CA (1) CA2892750A1 (https=)
HK (1) HK1212896A1 (https=)
IL (1) IL238658A0 (https=)
MX (1) MX2015006424A (https=)
RU (1) RU2015125349A (https=)
SG (1) SG11201503719WA (https=)
TW (1) TW201429992A (https=)
UY (1) UY35154A (https=)
WO (1) WO2014085596A1 (https=)
ZA (1) ZA201504659B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3831843A1 (en) 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN116496394B (zh) * 2022-01-26 2024-07-23 东莞市朋志生物科技有限公司 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
CA3245346A1 (en) * 2022-03-04 2023-09-07 Coagulant Therapeutics Corporation Camelid antibodies directed against activated protein C and their uses
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
ATE464374T1 (de) * 2000-10-02 2010-04-15 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20030203355A1 (en) * 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ES2385054T3 (es) * 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011500843A (ja) * 2007-10-26 2011-01-06 オクラホマ・メディカル・リサーチ・ファウンデーション 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
JP2014500874A (ja) * 2010-11-16 2014-01-16 メディミューン，エルエルシー 抗ｉｇｆ抗体を用いた治療レジメン
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
KR20150088869A (ko) 2015-08-03
EP2925351A4 (en) 2016-08-24
CA2892750A1 (en) 2014-06-05
MX2015006424A (es) 2015-08-14
WO2014085596A1 (en) 2014-06-05
AU2013352159A1 (en) 2015-06-04
ZA201504659B (en) 2017-11-29
AR093671A1 (es) 2015-06-17
BR112015012414A2 (pt) 2017-09-12
US20150307625A1 (en) 2015-10-29
IL238658A0 (en) 2015-06-30
JP2016501230A (ja) 2016-01-18
TW201429992A (zh) 2014-08-01
CN104812402A (zh) 2015-07-29
UY35154A (es) 2014-06-30
HK1212896A1 (zh) 2016-06-24
EP2925351A1 (en) 2015-10-07
SG11201503719WA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
RU2015125349A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)
JP2016501230A5 (https=)
ES2535365T3 (es) Tratamiento de trastornos relacionados con TNF alfa
JP7759067B2 (ja) 広域中和抗ｈｉｖ－１抗体およびその使用方法
RU2016129113A (ru) Антитела к pd-1 собак
JP2020039360A5 (https=)
IL301607B2 (en) Compositions and methods for growth factor modulation
RU2009149294A (ru) Антиген-связывающие белки, нацеленные на orf0657n s.aureus
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2016188209A5 (https=)
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2020514277A5 (https=)
HRP20220918T1 (hr) Anti-transtiretinska antitijela
JP2019527543A5 (https=)
JP2012519712A5 (https=)
FI3978522T3 (fi) Humaaneja vasta-aineita Fel d1:lle ja niiden käyttömenetelmiä
JP2018510617A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
KR20130043168A (ko) 이원 가변 도메인 면역글로불린 및 이의 용도
JP2014525933A5 (https=)
TW201313738A (zh) 人類類血管生成素蛋白３之人類抗體
JP2015522252A5 (https=)
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
JP2009537143A5 (https=)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20161128